Salarius Pharmaceuticals effects 1-for-15 reverse stock split to regain Nasdaq compliance

Decoy Therapeutics Inc.

Reverse split effective 5:00 p.m. ET on August 15, 2025; trading on split-adjusted basis from August 18, 2025.
Shares outstanding reduced from ~7.6M to ~509,000; no fractional shares, cash in lieu paid.
New CUSIP number 79400X503; authorized shares and par value unchanged.
Split approved by stockholders at July 8, 2025 special meeting; ratio set by Board.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Decoy Therapeutics Inc.: Filed a Certificate of Amendment to effect a 1-for-15 reverse stock split of common stock (effective 2025-08-15).

Change: charter amendment
Effective: 2025-08-15

Exact text from the filing

On August 15, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s amended and restated certificate of incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware , to effect a 1-for-15 reverse stock split (the “reverse split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”), effective at 5:00 p.m. Eastern Time on that date (the “Effective Date”).

View on SEC.gov

51 governance changes filed in the last 30 days. Browse all governance changes →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-25-000101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.